Health Care • Medicinal Chemicals and Botanical Products
$37.96 ▼ -0.14
(-0.37%)
MKT CAP: $5.10B • VOL: 1.42M
52W L $10 52W H $50
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$32
MEDIAN
$43
MEAN
$43
HIGH
$52
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE DFTX TAPE
DFTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $45.93 | $43.65 | 2025-02-14 | $34.54 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $47.83 | $44.79 | 2025-02-06 | $35.68 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $43.27 | $41.76 | 2025-01-29 | $36.44 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $38.72 | — | 2025-01-17 | $37.20 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $33.40 | $36.06 | 2025-01-09 | $33.78 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $45.17 | $39.48 | 2024-12-18 | $33.03 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $36.82 | $38.34 | 2024-12-04 | $35.30 | -4.3% | 48% | C |